Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 21;16(25):11280-11290.
doi: 10.1039/d5sc01030f. eCollection 2025 Jun 25.

Enhancing binding affinity predictions through efficient sampling with a re-engineered BAR method: a test on GPCR targets

Affiliations

Enhancing binding affinity predictions through efficient sampling with a re-engineered BAR method: a test on GPCR targets

Minkyu Kim et al. Chem Sci. .

Abstract

Computational approaches for predicting the binding affinity of ligand-receptor complex structures often fail to validate experimental results satisfactorily due to insufficient sampling. To address these challenges, recent emphasis has been placed on the re-sampling of new trajectories. In this study, we propose a simulation protocol that achieves efficient sampling by re-engineering the widely used Bennett acceptance ratio (BAR) method as a representative approach. We tested its efficacy across various membrane protein targets, including G-protein coupled receptors (GPCRs) with diverse structural landscapes and experimentally validated binding affinities, to verify its efficient applicability. Subsequently, using BAR-based binding free energy calculations, we confirmed correlations with experimental data, demonstrating the validity and performance of this computational approach.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): A. E. C. has a significant financial stake in and is the Founder and CEO of inCerebro Co., Ltd. Additionally, D. K. and S. L. were formerly affiliated with inCerebro and are now affiliated with Atomatrix. Contact: donghwanz@atomatrix.co.kr and sblee@atomatrix.co.kr.

Figures

Fig. 1
Fig. 1. Structural representation of the agonist-bound β1AR complex. (A) The superimposition of the active state (gray color) of the β1AR-nanobody complex with four agonists bound and corresponding inactive state (green color), as depicted in panel B. The structure of the nanobody in the active state is highlighted in black. (B) The structures of four ligands co-crystallized with eight β1ARs. (C) Linear correlation between the computational and experimental results of the binding free energies for four agonist-bound inactive (L) and active (H) states of β1AR. See ESI Table S5 for numerical data on BAR binding free energies.
Fig. 2
Fig. 2. Polar and nonpolar interactions in agonists bound to each β1AR in the inactive and active states, respectively. For the interaction analysis, the residues within the distance of 3.9 Å from the ligand and over the 40% of an interaction population in the entire MD trajectory were considered. Van der Waals contacts are depicted with light blue rays and hydrogen bonds were highlighted as red dotted lines with favorable geometry.
Fig. 3
Fig. 3. Comparison of binding modes of PSB36 bound to A1AR and A2AAR. (A) Superposition of PSB36 bound A1AR (blue ribbon) and A2AAR (pink ribbon). The PSB36 ligand in A1AR is represented with cyan carbon atoms, while the same ligand in A2AAR is shown with orange carbon atoms. (B) 2D structure of the PSB36 used in this study. (C) Competition binding experiments for wild-type and mutated A2A and A1 receptor bound PSB36. (D)–(E) Comparison of competition binding experiments (pKi) and binding free energies (ΔG) of the wild type and T270M (A1AR)/M270T (A2AAR) mutant for A1AR and A2AAR. In particular, a detailed comparison of experimental and computational binding affinities is presented in (E), with experimental and computational pKi predictions highlighted in blue and yellow colors. See ESI Table S6 for numerical data on BAR binding free energies.
Fig. 4
Fig. 4. Comparison of ligand-binding sites in the A1AR crystal structure and A3AR obtained by Alphafold2 prediction. (A) Overview of the A1AR in complex with DU172 crystal structure. (B) and (C) Superimposition of backbone ribbons of the A1AR structure in complex with PSB36 with A3AR structure ((B) side view, (C) extracellular view).
Fig. 5
Fig. 5. Molecular basis of adenosine receptors and binding free energy calculations in A1AR and A3AR. (A) and (B) Correlation between calculated binding free energies of A1AR (A) and A3AR ligands (B) and experimental Ki values. The coefficient of determination (R2) is shown in the figures as red. (C) and (D) Representative binding mode structures of the adenosine receptors bound to #18 in A1AR (C) and A3AR (D). See Table 1 for numerical data on BAR binding free energies.
Fig. 6
Fig. 6. Evaluation of the H264–E169 salt bridge using molecular dynamics followed by binding free energy calculation. (A) Difference in the orthosteric site accessibility between the A2AAR crystal structure bound to ZMA and a SAR structure (25d) used in this study for BAR free energy calculation. The SAR structure (25d) with the salt bridge formed and a 3PWH crystal structure without a salt bridge were colored in cyan and magenta, respectively. (B) Measurement of the minimum distance between the nitrogen atoms in the sidechain of H264 and the oxygen atoms in the sidechain of E169 for all SAR data. (C) Comparison of experimental binding affinity (Ki) with calculated BAR binding free energy results from the SAR data used, and relative energy stabilities (ΔΔG) from the 25d compound. (D) Linear correlation between experimental pKi and calculated binding free energy ΔG for a total of 9 SAR data.

Similar articles

References

    1. Miranda W. E. Noskov S. Y. Valiente P. A. J. Chem. Inf. Model. 2015;55:1867–1877. doi: 10.1021/acs.jcim.5b00012. - DOI - PubMed
    1. Genheden S. Ryde U. Expert Opin. Drug Discov. 2015;10:449–461. doi: 10.1517/17460441.2015.1032936. - DOI - PMC - PubMed
    1. Kumari R. Kumar R. Open Source Drug Discovery Consortium Lynn A. J. Chem. Inf. Model. 2014;54:1951–1962. doi: 10.1021/ci500020m. - DOI - PubMed
    1. Zwanzig R. W. J. Chem. Phys. 1954;22:1420–1426. doi: 10.1063/1.1740409. - DOI
    1. Beveridge D. L. DiCapua F. M. Annu. Rev. Biophys. Biophys. Chem. 1989;18:431–492. doi: 10.1146/annurev.bb.18.060189.002243. - DOI - PubMed

LinkOut - more resources